Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Shipping costs for liquefied natural gas (LNG) cargoes have tumbled to five-year lows as newly built carriers added to the ...

Asian spot liquefied natural gas (LNG) prices fell this week amid low demand during the Lunar New Year holiday in Asia, ...

Wall Street is pointing slightly lower in early trading but is on track to close the week with solid gains on healthy ...

Despite Trump’s fervent claims that Greenland’s 55,000 residents desire to join the US, both Denmark and Greenland’s local ...

Denmark has achieved one of the goals of the Green Tripartite Agreement by designating 75,000 hectares of untouched forest. This is part of the broader plan to enhance biodiversity and allow nature to ...

The 27th Conference of the Parties (COP27) to the United Nation’s Framework Convent on Climate Change was held in Egypt from 6 to ... in the report was Novo Nordisk, which has set itself a ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI targets.

However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.